PMC:7102560 / 11321-12063 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T137","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T138","span":{"begin":0,"end":4},"obj":"Disease"},{"id":"T139","span":{"begin":313,"end":321},"obj":"Disease"},{"id":"T140","span":{"begin":313,"end":317},"obj":"Disease"},{"id":"T141","span":{"begin":441,"end":449},"obj":"Disease"},{"id":"T142","span":{"begin":441,"end":445},"obj":"Disease"}],"attributes":[{"id":"A137","pred":"mondo_id","subj":"T137","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"SARS-CoV-2 reactivation will be a vexing and persistent problem. Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality. Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation. The latter point was often determined by our empirical experience. Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T77","span":{"begin":32,"end":33},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T78","span":{"begin":133,"end":138},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T79","span":{"begin":145,"end":146},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T80","span":{"begin":161,"end":162},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T81","span":{"begin":366,"end":371},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T82","span":{"begin":393,"end":394},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"SARS-CoV-2 reactivation will be a vexing and persistent problem. Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality. Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation. The latter point was often determined by our empirical experience. Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T32","span":{"begin":406,"end":410},"obj":"Chemical"},{"id":"T33","span":{"begin":601,"end":606},"obj":"Chemical"},{"id":"T34","span":{"begin":702,"end":707},"obj":"Chemical"},{"id":"T35","span":{"begin":730,"end":741},"obj":"Chemical"}],"attributes":[{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_33232"}],"text":"SARS-CoV-2 reactivation will be a vexing and persistent problem. Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality. Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation. The latter point was often determined by our empirical experience. Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application."}

{"project":"LitCovid-sentences","denotations":[{"id":"T138","span":{"begin":0,"end":64},"obj":"Sentence"},{"id":"T139","span":{"begin":65,"end":242},"obj":"Sentence"},{"id":"T140","span":{"begin":243,"end":465},"obj":"Sentence"},{"id":"T141","span":{"begin":466,"end":532},"obj":"Sentence"},{"id":"T142","span":{"begin":533,"end":742},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SARS-CoV-2 reactivation will be a vexing and persistent problem. Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality. Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation. The latter point was often determined by our empirical experience. Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application."}

{"project":"LitCovid-PubTator","denotations":[{"id":"352","span":{"begin":0,"end":10},"obj":"Species"},{"id":"353","span":{"begin":86,"end":94},"obj":"Species"},{"id":"354","span":{"begin":313,"end":323},"obj":"Species"},{"id":"355","span":{"begin":441,"end":451},"obj":"Species"},{"id":"356","span":{"begin":95,"end":103},"obj":"Disease"},{"id":"357","span":{"begin":232,"end":241},"obj":"Disease"}],"attributes":[{"id":"A352","pred":"tao:has_database_id","subj":"352","obj":"Tax:2697049"},{"id":"A353","pred":"tao:has_database_id","subj":"353","obj":"Tax:9606"},{"id":"A354","pred":"tao:has_database_id","subj":"354","obj":"Tax:2697049"},{"id":"A355","pred":"tao:has_database_id","subj":"355","obj":"Tax:2697049"},{"id":"A356","pred":"tao:has_database_id","subj":"356","obj":"MESH:D007239"},{"id":"A357","pred":"tao:has_database_id","subj":"357","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SARS-CoV-2 reactivation will be a vexing and persistent problem. Considering numerous patients infected or previously exposed to the virus, such a problem poses a major public health burden in terms of global morbidity and possibly mortality. Currently, we did not find reliable markers in predicting the risk of SARS-CoV-2 reactivation, nor there are any validated tests to determine whether a particular drug or therapy is associated with SARS-CoV-2 reactivation. The latter point was often determined by our empirical experience. Although decades of the experiences helped us to identify important drugs and to manage these situations appropriately, we could not accurately evaluate the risk of the drugs prior to its clinical application."}